Skip to content
Fomepizole
Antizol (fomepizole) is a small molecule pharmaceutical. Fomepizole was first approved as Antizol on 1997-12-04. It is used to treat poisoning in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
chemically-induced disordersD064419
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Fomepizole
Tradename
Company
Number
Date
Products
ANTIZOLPar PharmaceuticalN-020696 DISCN1997-12-04
1 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
antizolNew Drug Application2009-07-27
fomepizoleANDA2023-02-10
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
poisoningEFO_0008546D011041T65.91
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Fomepizole, Antizol, Par Pharm Inc
75538632027-06-30DS, DP
ATC Codes
V: Various drug classes in atc
V03: All other therapeutic products
V03A: All other therapeutic products
V03AB: Antidotes
V03AB34: Fomepizole
HCPCS
Code
Description
J1451
Injection, fomepizole, 15 mg
Clinical
Clinical Trials
56 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Prostatic neoplasmsD011471C6141423242
Congenital adrenal hyperplasiaD000312E25.011
Premenstrual syndromeD011293N94.311
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AdenocarcinomaD000230346
Bone neoplasmsD001859EFO_0003820D1611
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Polycystic ovary syndromeD011085EFO_0000660E28.22136
Castration-resistant prostatic neoplasmsD06412911
InfertilityD007246EFO_000054511
Ovarian neoplasmsD010051EFO_0003893C5611
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HyperandrogenismD01758811
Metabolic syndromeD024821EFO_0000195E88.8111
Acne vulgarisD000152EFO_0003894L7011
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameFOMEPIZOLE
INNfomepizole
Description
Fomepizole is a member of the class of pyrazoles that is 1H-pyrazole substituted by a methyl group at position 4. It has a role as an antidote, a protective agent and an EC 1.1.1.1 (alcohol dehydrogenase) inhibitor. It derives from a hydride of a 1H-pyrazole.
Classification
Small molecule
Drug class
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cc1cn[nH]c1
Identifiers
PDB
CAS-ID7554-65-6
RxCUI15226
ChEMBL IDCHEMBL1308
ChEBI ID5141
PubChem CID3406
DrugBankDB01213
UNII ID83LCM6L2BY (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 516 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
434 adverse events reported
View more details